Filana Therapeutics, Inc.
FLNA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001069530
No open-market purchases or sales by Filana Therapeutics, Inc. insiders were filed in the last 90 days; 85 institutions reported holding it in 13F filings for Q2 2026, worth $15.1M in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Filana Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 181
- +16 vs. Q2 2021
- Shares held
- 12.2M
- +1.34M (+12.3%) vs. Q2 2021
- Total value
- $757.3M
- −$135.4M (−15.2%) vs. Q2 2021
- New holders
- 54
- 70 more added
- Sold out
- 38
- 41 more reduced
4 institutions that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FLNA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 85 | $15.1M |
| Q1 2026 | 101 | $23.1M |
| Q4 2025 | 107 | $27.3M |
| Q3 2025 | 103 | $40.1M |
| Q2 2025 | 97 | $22.1M |
| Q1 2025 | 117 | $23.6M |
| Q4 2024 | 137 | $41.1M |
| Q3 2024 | 161 | $412.5M |
| Q2 2024 | 145 | $164.6M |
| Q1 2024 | 142 | $235.3M |
| Q4 2023 | 153 | $313.5M |
| Q3 2023 | 141 | $215.4M |
| Q2 2023 | 152 | $286.8M |
| Q1 2023 | 145 | $287.9M |
| Q4 2022 | 153 | $332.5M |
| Q3 2022 | 174 | $438.9M |
| Q2 2022 | 149 | $279.2M |
| Q1 2022 | 163 | $390.2M |
| Q4 2021 | 171 | $504.1M |
| Q3 2021 | 181 | $757.3M |
| Q2 2021 | 169 | $893.4M |
| Q1 2021 | 128 | $458.2M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Filana Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −5,362−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −5,104−100.0% | Sold out |
| Panagora Asset Management Inc | 0 | $0 | 0.00% | −3,562−100.0% | Sold out |
| Quilter Plc | 0 | $0 | 0.00% | −3,434−100.0% | Sold out |
| Sigma Planning Corp | 0 | $0 | 0.00% | −3,123−100.0% | Sold out |
| Souders Financial Advisors | 0 | $0 | 0.00% | −3,116−100.0% | Sold out |
| Wetherby Asset Management Inc | 0 | $0 | 0.00% | −3,000−100.0% | Sold out |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −2,488−100.0% | Sold out |
| Intersect Capital LLC | 0 | $0 | 0.00% | −2,252−100.0% | Sold out |
| Maverick Capital LtdSuperinvestorMaverick Capital | 0 | $0 | 0.00% | −1,637−100.0% | Sold out |
| Personal Wealth Partners | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| tru Independence LLC | 0 | $0 | 0.00% | −940−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −921−100.0% | Sold out |
| Neo Ivy Capital Management | 0 | $0 | 0.00% | −665−100.0% | Sold out |
| Brewin Dolphin Ltd | 0 | $0 | 0.00% | −280−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −75−100.0% | Sold out |
| Prentice Wealth Management LLC | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| TD Private Client Wealth LLC | 0 | $0 | 0.00% | −7−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Coe Capital Management, LLC | – | – | – | – | Not filed |
| Pictet Asset Management Ltd | – | – | – | – | Not filed |
| Smith Asset Management Group LP | – | – | – | – | Not filed |
| CWM, LLC | – | – | – | – | Not filed |